Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02336165 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 8
- Study locations
NCT02336165 is a Phase 2 study of Glioblastoma that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 159 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (47% higher). The trial reports 8 study locations across 6 states.
The verdict
NCT02336165, a Phase 2 study of Glioblastoma, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is an ongoing Phase 2, open-label, multicenter, non-randomized study of MEDI4736 (durvalumab) in subjects with glioblastoma (GBM) enrolled into 5 non-comparative cohorts. Primary study objectives, which vary by cohort due to differences in subject populations, include evaluation of the clinical efficacy as measured by the overall survival (OS) rate at 12 months (Cohort A), progression-free survival (PFS) at 6 months (Cohorts B, B2, and B3), and OS at 6 months (Cohort C). For all cohorts, secondary objectives include evaluation of the safety/tolerability and clinical efficacy of study treatment, and exploratory objectives include evaluation of the neurologic function and correlative biomarkers.
Conditions Studied
Interventions
- BIOLOGICAL Bevacizumab
- DRUG Durvalumab
- RADIATION Standard radiotherapy
Study Locations (8)
California
- Research Facility - Los Angeles
- Research Facility - San Francisco
Massachusetts
- Research Facility - Boston
- Research Facility - Boston
Maryland
- Research Facility - Baltimore
Missouri
- Research Facility - St Louis
New York
- Research Facility - New York
Other
- Research Facility - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2015-02-26 |
| Est. Completion | 2021-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02336165
The ClinicalTrials.gov registry entry for NCT02336165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (47% higher). The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT02336165 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Massachusetts, Maryland.
Frequently Asked Questions
What is clinical trial NCT02336165 about?
NCT02336165 is a clinical study titled "Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma". This is an ongoing Phase 2, open-label, multicenter, non-randomized study of MEDI4736 (durvalumab) in subjects with glioblastoma (GBM) enrolled into 5 non-comparative cohorts. Primary study objectives, which vary by cohort due to differences in subject populations, include evaluation of the clinical...
What is the current status of trial NCT02336165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2015-02-26. Estimated completion is 2021-07-06.
What conditions does trial NCT02336165 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02336165?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), Durvalumab (DRUG), Standard radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02336165?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02336165 being conducted?
This trial has 8 study locations across California, Maryland, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.